Adductor Canal Block With Periarticular Injection and IPACK (ACB/PAI/IPACK) Versus Periarticular Injection (PAI)

• Status: Unknown status
• Trial end date: 2019-01-31
• Target enrollment: 0
• Participant gender: All

Summary

A comparison of two pain control methods - the combination of Adductor Canal Block (ACB)/Periarticular Injection (PAI)/Infiltration of the interspace between the popliteal artery and the capsule of the posterior knee (IPACK) versus the Periarticular Injection (PAI)

• in patients undergoing total knee arthroplasty. Primary outcome is NRS pain scores with ambulation on postoperative day one (24 hours post-block administration).

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Hospital for Special Surgery, New York
• Treatments: BB 1101; Bupivacaine; Cefazolin; Dexamethasone; Dexamethasone acetate; Epinephrine; Epinephryl borate; Methylprednisolone; Methylprednisolone acetate; Methylprednisolone Hemisuccinate; Prednisolone; Prednisolone acetate; Prednisolone hemisuccinate; Prednisolone phosphate; Racepinephrine

Criteria

Inclusion Criteria:

• Patients with osteoarthritis scheduled for a primary either partial or total knee arthroplasty with a participating surgeon

• Age 18 to 80 years

• Planned use of regional anesthesia

• Ability to follow study protocol

• English speaking (secondary outcomes include questionnaires validated in English only)

• Patients of participating surgeons

Exclusion Criteria:

• Hepatic or renal insufficiency

• Younger than 18 years old and older than 80

• Patients undergoing general anesthesia

• Allergy or intolerance to one of the study medications

• BMI > 40

• Diabetes

• ASA of IV

• Chronic gabapentin/pregabalin use (regular use for longer than 3 months)

• Chronic opioid use (taking opioids for longer than 3 months, or daily oral morphine equivalent of >5mg/day for one month)

• Patients with severe valgus deformity and flexion contracture